Perrigo has seen its share price climb in the short term, yet its longer track record is weak. This puts a spotlight on whether the current valuation lines up with its sales base. With the business reshaping its portfolio and refocusing on consumer self care, the question is how much revenue power investors are really paying for at today's price.
-
The stock has fallen 53.9% over the past 5 years, which makes the current tag an important test of how the market now rates Perrigo's ability to convert its sales into shareholder value.
-
The agreed sale of the Infant Formula unit and earlier divestment of the Dermacosmetics business may support a simpler portfolio and different margin mix. This can change how investors read each dollar of sales against the Fair Ratio benchmark.
-
There is a second opinion on Perrigo worth weighing. See what analysts think Perrigo's shares could be worth .
The issue now is whether Perrigo's current share price is adequately backed by its sales when judged against the Fair Ratio benchmark.
If you are considering whether Perrigo's price is aligned with its current sales, it may be helpful to compare this question across 39 high quality undervalued stocks .
Is Perrigo Still Cheap on Sales?
P/S works well for Perrigo because investors are effectively paying for a consumer self care revenue base rather than a single blockbuster drug pipeline. On this lens, the stock trades on a P/S ratio of 0.5x, compared with a Pharmaceuticals industry average of 4.2x and a peer group around 13.7x.
The Fair Ratio model, which adjusts the P/S yardstick for Perrigo's margins, scale and risk profile, still points to a higher multiple than where the shares currently trade, so the price screens undervalued on this measure. Because the agreed sale of the Infant Formula business aims to simplify the portfolio and shift the margin mix, the current discount on P/S suggests the market is not fully crediting those planned changes to the earnings base yet. Explore the numbers behind Perrigo's P/S valuation .
The Perrigo Narrative: What Would Justify Today's Price?
Narratives for Perrigo pick up where the valuation puzzle leaves off and spell out which paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or less than today's price, based on scenarios shared on Simply Wall St's Community page. Rather than presenting a single P/S output, these stories unpack the future that number reflects so you can watch over time whether those conditions actually show up.
Community views on Perrigo now split between a cleaner self care story that looks underappreciated and a more cautious read on growth and execution risk.
Bull case: 12% undervalued
"Strategic portfolio simplification, including the recent sale of the Dermacosmetics business, allows Perrigo to focus investment on core, higher-growth segments..."
Discover why this Narrative puts Perrigo at 12% undervalued .
Bear case: 6% overvalued
"The current numbers and governance backdrop imply a share price that already gives Perrigo credit for successful execution on savings, portfolio actions, and innovation..."
Explore why this Narrative puts Perrigo at 6% overvalued .
Before acting on Perrigo's valuation, there is one more signal to check
Price multiples tell you what the market pays for Perrigo today. The next question is how professional analysts think this business might look a few years from now, and how that compares to the current tag. Explore where analysts expect Perrigo to be in a few years .
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PRGO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
